JP6591964B2 - Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 - Google Patents

Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 Download PDF

Info

Publication number
JP6591964B2
JP6591964B2 JP2016509455A JP2016509455A JP6591964B2 JP 6591964 B2 JP6591964 B2 JP 6591964B2 JP 2016509455 A JP2016509455 A JP 2016509455A JP 2016509455 A JP2016509455 A JP 2016509455A JP 6591964 B2 JP6591964 B2 JP 6591964B2
Authority
JP
Japan
Prior art keywords
seq
icosl
vnar
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016509455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016524592A (ja
JP2016524592A5 (enExample
Inventor
ジェーン バレル，キャロライン
ジェーン バレル，キャロライン
ジェームス ジョナサン フィンレイ，ウィリアム
ジェームス ジョナサン フィンレイ，ウィリアム
ダーマンイン−シーハン，アルフレッド
Original Assignee
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン, ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン filed Critical ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン
Publication of JP2016524592A publication Critical patent/JP2016524592A/ja
Publication of JP2016524592A5 publication Critical patent/JP2016524592A5/ja
Application granted granted Critical
Publication of JP6591964B2 publication Critical patent/JP6591964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP2016509455A 2013-04-23 2014-04-23 Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離 Active JP6591964B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361815043P 2013-04-23 2013-04-23
US61/815,043 2013-04-23
PCT/EP2014/058276 WO2014173975A1 (en) 2013-04-23 2014-04-23 Isolation of therapeutic target specific vnar domains to icosl

Publications (3)

Publication Number Publication Date
JP2016524592A JP2016524592A (ja) 2016-08-18
JP2016524592A5 JP2016524592A5 (enExample) 2017-06-01
JP6591964B2 true JP6591964B2 (ja) 2019-10-16

Family

ID=50543598

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016509455A Active JP6591964B2 (ja) 2013-04-23 2014-04-23 Ｉｃｏｓｌへの治療上の標的特異的ｖｎａｒドメインの単離
JP2016509450A Active JP6616284B2 (ja) 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016509450A Active JP6616284B2 (ja) 2013-04-23 2014-04-23 特異的結合分子の人工ライブラリー

Country Status (11)

Country Link
US (3) US10472410B2 (enExample)
EP (3) EP3683312B1 (enExample)
JP (2) JP6591964B2 (enExample)
KR (2) KR102320189B1 (enExample)
CN (2) CN105492610B (enExample)
AU (3) AU2014257549B2 (enExample)
BR (2) BR112015026729A2 (enExample)
CA (2) CA2909921C (enExample)
DK (1) DK2989203T3 (enExample)
RU (2) RU2015146419A (enExample)
WO (2) WO2014173975A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
EP3683312B1 (en) 2013-04-23 2022-09-07 Elasmogen Limited Synthetic library of specific binding molecules
EP3160995A2 (en) * 2014-06-26 2017-05-03 Ossianix Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
US11001640B2 (en) * 2014-11-03 2021-05-11 Merck Patent Gmbh Methods for generating bispecific shark variable antibody domains and use thereof
WO2016077840A2 (en) 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
CN107130300A (zh) * 2016-10-08 2017-09-05 深圳劲宇生物科技有限公司 一种dna编码分子库的合成方法及dna模板
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
CA3075367A1 (en) 2017-09-27 2019-04-04 Elasmogen Ltd Specific binding molecules
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
GB201721802D0 (en) * 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
US12351642B2 (en) 2018-09-14 2025-07-08 Ossianix, Inc. TFR-specific binding moieties and transcytosis method to select VNARs that cross cellular barriers
CN111197074B (zh) * 2018-11-20 2023-08-15 深圳华大生命科学研究院 条纹斑竹鲨免疫球蛋白新抗原受体可变区库引物及应用
US20220130494A1 (en) * 2019-02-11 2022-04-28 Neal W. Woodbury Systems, methods, and media for molecule design using machine learning mechanisms
GB201906997D0 (en) * 2019-05-17 2019-07-03 Elasmogen Ltd Conjugates
GB201908886D0 (en) * 2019-06-20 2019-08-07 Almac Discovery Ltd Anthracycline derivatives
JP7765090B2 (ja) * 2020-05-01 2025-11-06 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ナノボディ及びナノボディ親和性を同定するための組成物及び方法
CN112301431B (zh) * 2020-08-12 2023-01-31 华东理工大学 基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
GB202020154D0 (en) * 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
EP4141028A1 (en) 2021-08-31 2023-03-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Personalized vnar-based chimeric antigen receptors (vnar-car) for the treatment of clonal b-and t cell malignancies, and methods for producing vnar-cars
GB202407865D0 (en) 2024-06-03 2024-07-17 Elasmogen Ltd Self immolative compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008419D0 (en) 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20050048617A1 (en) * 2003-08-18 2005-03-03 Medimmune, Inc. Humanization of antibodies
EP1670932B1 (en) * 2003-08-27 2011-03-30 Proterec Ltd Libraries of recombinant chimeric proteins
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
MXPA06014075A (es) * 2004-06-03 2007-03-15 Novimmune Sa Anticuerpos anti-cd3 y metodos de uso de los mismos.
WO2006003999A1 (ja) * 2004-07-05 2006-01-12 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトb7rp-1抗体およびその抗体フラグメント
EP1869192B1 (en) * 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
WO2006099747A1 (en) 2005-03-25 2006-09-28 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
DK1915398T3 (en) 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
JP2010505435A (ja) 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
WO2009026638A1 (en) 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
US8524863B2 (en) * 2008-10-06 2013-09-03 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
BRPI0920810A2 (pt) * 2008-10-07 2015-12-22 Zap Holdings Ltd sincronização de bancos de dados relacionais com cubos de olap
US8496933B2 (en) * 2009-11-04 2013-07-30 Laboratorios Silanes, S.A. De C.V. VHNAR anti-cytokine domains
US20140154241A1 (en) * 2010-12-03 2014-06-05 Cyclogenix Ltd Binding peptides i
WO2013167883A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
CN103031304A (zh) * 2012-12-27 2013-04-10 苏州大学 一种微小rna用于调控b7-h2基因表达
EP3683312B1 (en) 2013-04-23 2022-09-07 Elasmogen Limited Synthetic library of specific binding molecules

Also Published As

Publication number Publication date
WO2014173959A2 (en) 2014-10-30
KR102320189B1 (ko) 2021-11-03
JP2016524592A (ja) 2016-08-18
EP2989204A1 (en) 2016-03-02
AU2014257549A1 (en) 2015-11-26
EP2989204B1 (en) 2019-03-20
WO2014173975A1 (en) 2014-10-30
US20160068600A1 (en) 2016-03-10
JP2016524463A (ja) 2016-08-18
US10202438B2 (en) 2019-02-12
JP6616284B2 (ja) 2019-12-04
CA2909921A1 (en) 2014-10-30
BR112015026729A2 (pt) 2017-09-05
RU2015146418A3 (enExample) 2018-05-07
CN105531370A (zh) 2016-04-27
EP3683312A3 (en) 2020-09-16
WO2014173959A3 (en) 2015-01-29
KR20160010466A (ko) 2016-01-27
US11459377B2 (en) 2022-10-04
DK2989203T3 (da) 2020-02-17
US20160176951A1 (en) 2016-06-23
RU2015146418A (ru) 2017-05-26
BR112015026716A2 (pt) 2017-09-05
AU2019206064A1 (en) 2019-08-08
AU2014257549B2 (en) 2019-04-18
KR20160015220A (ko) 2016-02-12
RU2015146419A (ru) 2017-05-26
EP2989203A2 (en) 2016-03-02
EP3683312A2 (en) 2020-07-22
US10472410B2 (en) 2019-11-12
CN105492610A (zh) 2016-04-13
US20200002403A1 (en) 2020-01-02
AU2014257565A1 (en) 2015-11-26
EP3683312B1 (en) 2022-09-07
CA2909921C (en) 2022-12-06
CA2909923A1 (en) 2014-10-30
EP2989203B1 (en) 2019-11-13
CN105492610B (zh) 2020-08-25

Similar Documents

Publication Publication Date Title
EP2989204B1 (en) Isolation of therapeutic target specific vnar domains to icosl
CN108473987B (zh) 具有改变的多样性支架结构域的结合成员
CN110540590B (zh) 一种自免疫抑制物的开发和应用
US20200115702A1 (en) Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
JP2021521781A (ja) 三価三重特異性抗体構築物
EP4177267A1 (en) Anti-surrogate light chain antibodies
JP2021518168A (ja) 拮抗的抗原結合タンパク質
US20240376639A1 (en) Fast-track humanisation of specific binding molecules
TW202542177A (zh) 可活化融合蛋白及使用方法
CN120865416B (zh) 抗mica/b抗体及其应用
WO2026072963A1 (en) Bispecific antibodies that bind tnfrsf25 and il-23/il-23r

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170414

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180306

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190919

R150 Certificate of patent or registration of utility model

Ref document number: 6591964

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250